相关实验视频

Updated: Sep 12, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

释放潜力:组织突变丰度作为第三代EGFR-TKI在NSCLC中的疗效预测因素

Ruiqi Wang¹, Hongfei Wei², Chunjing Qu³

¹Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China; Department of Hematology, the First Hospital of Jilin University, Changchun 130021, China.

Lung cancer (Amsterdam, Netherlands)

|August 7, 2025

概括

组织突变丰度是第三代EGFR-TKI在非小细胞肺癌 (NSCLC) 疗效的关键预测因素. 高丰度与更长的无进展生存相关,而低丰度可能表明耐药性,需要个性化治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

第三代EGFR-TKI是EGFR突变不可切除的NSCLC的第一线治疗方法.
组织突变丰度在预测TKI疗效方面的作用仍未得到充分研究.
优化向治疗需要了解影响治疗反应的因素.

研究的目的:

基于NSCLC患者的组织突变丰度,比较一线第三代EGFR-TKI的疗效.
为了确定治疗反应和无进展生存的预测因素.

主要方法:

追溯分析了159名无法切除的NSCLC患者的EGFR敏感突变.
在高基因突变丰度组和低基因突变丰度组之间比较治疗反应和中位数无进展生存期 (mPFS).
单变量和多变量分析以确定mPFS的风险因素.

主要成果:

高突变丰度组的客观响应率 (88%对66.7%) 和疾病控制率 (97.2%对80.4%) 显着更高.
高富裕群体的mPFS较长 (22个月与17个月).
疾病进展模式在各组之间是相似的,没有统计学意义.

结论:

组织突变丰度是第三代TKI在EGFR突变NSCLC中的有效性的重要预测指标.
高突变丰度与优越的治疗结果和更长的mPFS有关.
基于突变丰度和其他因素的个性化治疗策略需要进一步的研究.

关键词:

皮肤表皮生长因子受体.非小细胞肺癌是非小细胞肺癌.组织突变的丰富性组织突变的丰富性铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...